Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study.

IF 0.9 4区医学 Q4 CLINICAL NEUROLOGY

Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2025-05-30 DOI:10.18071/isz.78.0163

Aysel Büşra Şişman, Merve Savaş, Gizem Koral, Muhammet Duran Bayar, Oğuz Yildiz, Aytül Mutlu, Vuslat Yilmaz, Erdem Tüzün, Özlem Cokar

{"title":"Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study.","authors":"Aysel Büşra Şişman, Merve Savaş, Gizem Koral, Muhammet Duran Bayar, Oğuz Yildiz, Aytül Mutlu, Vuslat Yilmaz, Erdem Tüzün, Özlem Cokar","doi":"10.18071/isz.78.0163","DOIUrl":null,"url":null,"abstract":"Background and purpose: The role of synaptic dysfunction in focal epilepsy of unknown cause is not well understood. Neurogranin is a post-synaptic protein used as a biomarker of synaptic disintegration in patients with dementia.Methods: To evaluate the association between synaptic loss, cognitive impairment and seizure activity in epilepsy, we collected sera of 51 patients with focal epilepsy of unknown cause, 26 with frontal lobe epilepsy (FLE) and 25 with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLEHS), and 25 healthy controls. Serum neurogranin levels were measured by ELISA and we sought for potential correlations between neurogranin levels versus clinical features, cognitive test and quality of life scores of the patients.Results: Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels.Conclusion: Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown. Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures. Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"78 5-6","pages":"163-168"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ideggyogyaszati Szemle-Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18071/isz.78.0163","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: The role of synaptic dysfunction in focal epilepsy of unknown cause is not well understood. Neurogranin is a post-synaptic protein used as a biomarker of synaptic disintegration in patients with dementia.

Methods: To evaluate the association between synaptic loss, cognitive impairment and seizure activity in epilepsy, we collected sera of 51 patients with focal epilepsy of unknown cause, 26 with frontal lobe epilepsy (FLE) and 25 with mesial temporal lobe epilepsy with hippocampal sclerosis (MTLEHS), and 25 healthy controls. Serum neurogranin levels were measured by ELISA and we sought for potential correlations between neurogranin levels versus clinical features, cognitive test and quality of life scores of the patients.

Results: Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels.

Conclusion: Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown. Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures. Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.

查看原文本刊更多论文

病因不明的局灶性癫痫治疗抵抗患者显示神经颗粒蛋白水平降低：一项初步研究。

背景与目的：突触功能障碍在病因不明的局灶性癫痫中的作用尚不清楚。神经颗粒蛋白是一种突触后蛋白，被用作痴呆患者突触解体的生物标志物。方法：收集51例局灶性不明原因癫痫患者、26例额叶癫痫（FLE）患者、25例内侧颞叶癫痫伴海马硬化（MTLEHS）患者和25例健康对照者的血清，以评价突触丧失、认知功能障碍与癫痫发作活动的关系。采用ELISA法测定血清神经颗粒蛋白水平，寻找神经颗粒蛋白水平与患者临床特征、认知测试和生活质量评分之间的潜在相关性。结果：与FLE患者和健康对照相比，MTLE-HS患者的神经颗粒蛋白水平显著降低，但与任何临床和认知变量无关。治疗耐药的FLE和MTLE-HS患者的神经颗粒蛋白水平均显著降低。结论：我们的研究结果表明，MTLE-HS患者的突触蛋白产生减少，而不是突触破坏增加。神经粒蛋白的减少与抗癫痫治疗的抵抗有关，这意味着该蛋白在控制癫痫发作中的作用。神经粒蛋白可作为局灶性癫痫发作活动监测的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ideggyogyaszati Szemle-Clinical Neuroscience CLINICAL NEUROLOGY-NEUROSCIENCES

CiteScore

1.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The aim of Clinical Neuroscience (Ideggyógyászati Szemle) is to provide a forum for the exchange of clinical and scientific information for a multidisciplinary community. The Clinical Neuroscience will be of primary interest to neurologists, neurosurgeons, psychiatrist and clinical specialized psycholigists, neuroradiologists and clinical neurophysiologists, but original works in basic or computer science, epidemiology, pharmacology, etc., relating to the clinical practice with involvement of the central nervous system are also welcome.